Latest news
Celcuity Schedules Release of Second Quarter 2026 Financial Results and Webcast/Conference Call - The Manila TimesThe Manila Times · Thu, 06 Aug 2026 12:44:26 GMTFDA Roundup: Oncology Drug Approvals in 2026 - Cancer Therapy AdvisorCancer Therapy Advisor · Wed, 05 Aug 2026 04:00:00 GMTFDA Green-Lights Five New Treatment Options for Breast Cancer - Cancer HealthCancer Health · Mon, 03 Aug 2026 13:01:12 GMTGedatolisib/Fulvestrant Earns NCCN Category 1 Listing for HR+/HER2– Breast Cancer - CancerNetworkCancerNetwork · Mon, 03 Aug 2026 12:08:52 GMTIs REVTORPYK’s First‑in‑Class FDA Approval Reframing the Investment Case For Celcuity (CELC)? - webull.comwebull.com · Mon, 03 Aug 2026 06:22:36 GMTNewly FDA-approved Revtorpyk wins NCCN listing - The Pharma LetterThe Pharma Letter · Sat, 01 Aug 2026 14:27:59 GMTNewly FDA-Approved REVTORPYK™ (gedatolisib) Included in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines for HR+/HER2- Locally Advanced or Metastatic Breast Cancer - Yahoo FinanceYahoo Finance · Thu, 30 Jul 2026 12:30:00 GMTFDA Approves Revtorpyk for a Breast Cancer Subgroup That Had Been Left Out of Targeted Treatment - Medical DailyMedical Daily · Mon, 27 Jul 2026 11:50:10 GMT